source Post navigation SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes – Yahoo Finance Diabetes program ‘a risk to students’ – The Australian